Pharvaris Seeks Trial Patients to Test Its Oral Therapy for HAE Attacks

Pharvaris Seeks Trial Patients to Test Its Oral Therapy for HAE Attacks

312328

Pharvaris Seeks Trial Patients to Test Its Oral Therapy for HAE Attacks

Pharvaris is actively recruiting people with hereditary angioedema (HAE) types 1 or 2 for two clinical trials testing its investigational oral therapy PHVS416 as either an on-demand or prophylactic (preventive) treatment for swelling attacks. Results from both studies are expected next year. The Phase 2 trial RAPIDe-1 (NCT04618211), which started earlier this year, is testing PHVS416 as an on-demand treatment for swelling attacks. In this two-part trial, participants are first given a dose of the…

You must be logged in to read/download the full post.